# Labcorp (LH) — Earnings

LH · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/lh/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $4.99 |
| EPS estimate | $4.78 |
| EPS surprise | +4.41% |
| Revenue surprise | +0.59% |
| Revenue | $3.7B |
| Revenue estimate | $3.7B |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/920148/000092014826000175/lh-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/0db0e283-8f69-8433-de5e-4dab6c09c10d.html) |

Labcorp reported Q2 2026 results on July 30, 2026. Earnings per share were $4.99, ahead of the $4.78 estimate by 4.41%. Revenue was $3.7 billion, above the $3.7 billion consensus by 0.59%. Compared with Q2 2025, EPS rose about 15% from $4.35 and revenue rose about 6% from $3.5 billion.

Annual EPS fell from $17.09 in 2022 to $13.38 in 2023, then rose to $14.57 in 2024 and $16.44 in 2025. The first half of 2026 adds up to $9.24, about 13% more than the $8.19 of the first half of 2025. The highest quarter in the table was Q3 2021, at $5.86 per share, and the lowest was Q1 2023, at $3.28. Quarterly revenue moved from $3.8 billion in Q1 2023 to $3.0 billion in Q2 2023, and it has climbed back since. Over the last 20 quarters, Labcorp topped the EPS estimate 18 times. The only misses were Q1 and Q2 2023.

Labcorp reported Q3 results between October 24 and October 28 in each of the past five years. That points to late October 2026 for the next report. It will show how Q3 2026 compares with the $4.18 per share earned a year earlier.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | $4.78 | $4.99 | 4.41% | $3.7B | $3.7B |
| Q1 2026 | Apr 30, 2026 | $4.11 | $4.25 | 3.42% | $3.5B | $3.5B |
| Q4 2025 | Feb 17, 2026 | $3.95 | $4.07 | 3.17% | $3.6B | $3.5B |
| Q3 2025 | Oct 28, 2025 | $4.13 | $4.18 | 1.21% | $3.6B | $3.6B |
| Q2 2025 | Jul 24, 2025 | $4.17 | $4.35 | 4.36% | $3.5B | $3.5B |
| Q1 2025 | Apr 29, 2025 | $3.74 | $3.84 | 2.63% | $3.4B | $3.3B |
| Q4 2024 | Feb 6, 2025 | $3.39 | $3.45 | 1.70% | $3.3B | $3.3B |
| Q3 2024 | Oct 24, 2024 | $3.47 | $3.50 | 0.79% | $3.3B | $3.3B |
| Q2 2024 | Aug 1, 2024 | $3.78 | $3.94 | 4.34% | $3.2B | $3.2B |
| Q1 2024 | Apr 25, 2024 | $3.48 | $3.68 | 5.61% | $3.1B | $3.2B |
| Q4 2023 | Feb 15, 2024 | $3.26 | $3.30 | 1.32% | $3.0B | $3.0B |
| Q3 2023 | Oct 26, 2023 | $3.33 | $3.38 | 1.40% | $3.0B | $3.1B |
| Q2 2023 | Jul 27, 2023 | $3.84 | $3.42 | -10.84% | $3.8B | $3.0B |
| Q1 2023 | Apr 25, 2023 | $3.40 | $3.28 | -3.44% | $3.7B | $3.8B |
| Q4 2022 | Feb 16, 2023 | $3.53 | $3.56 | 0.89% | $3.7B | $3.7B |
| Q3 2022 | Oct 27, 2022 | $4.01 | $4.02 | 0.28% | $3.8B | $3.6B |
| Q2 2022 | Jul 28, 2022 | $4.04 | $4.26 | 5.56% | $3.8B | $3.7B |
| Q1 2022 | Apr 28, 2022 | $5.13 | $5.25 | 2.24% | $4.0B | $3.9B |
| Q4 2021 | Feb 10, 2022 | $5.13 | $5.82 | 13.48% | $3.9B | $4.1B |
| Q3 2021 | Oct 28, 2021 | $4.22 | $5.86 | 38.71% | $3.6B | $4.1B |

## Frequently Asked Questions

### When did Labcorp (LH) last report earnings?

Labcorp last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did LH beat earnings estimates?

Yes. Labcorp reported EPS of $4.99 for Q2 2026 against a $4.78 estimate — a 4.41% beat.

### How much revenue did LH report last quarter?

Labcorp reported $3.7B in revenue for Q2 2026, against a consensus estimate of $3.7B.

## Similar Stocks

- [AMN](https://www.lighthorse.io/tickers/amn) — AMN Healthcare Services Inc
- [TMO](https://www.lighthorse.io/tickers/tmo) — Thermo Fisher Scientific Inc Common Stock
- [MEDP](https://www.lighthorse.io/tickers/medp) — Medpace Holdings, Inc. - Common Stock
- [HSIC](https://www.lighthorse.io/tickers/hsic) — Henry Schein, Inc. - Common Stock
- [CAH](https://www.lighthorse.io/tickers/cah) — Cardinal Health, Inc. Common Stock
- [MCK](https://www.lighthorse.io/tickers/mck) — McKesson Corporation Common Stock
- [CHE](https://www.lighthorse.io/tickers/che) — Chemed Corp
- [WST](https://www.lighthorse.io/tickers/wst) — West Pharmaceutical Services, Inc. Common Stock
- [DGX](https://www.lighthorse.io/tickers/dgx) — Quest Diagnostics Incorporated Common Stock
- [BIO](https://www.lighthorse.io/tickers/bio) — Bio-Rad Laboratories, Inc. Class A Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).